ATI RN
ATI Pharmacology Proctored Exam
1. A client is being educated by a healthcare provider about Terbutaline. Which of the following statements by the client indicates understanding of the teaching?
- A. This medication will stop my contractions.
- B. This medication will prevent vaginal bleeding.
- C. This medication will promote blood flow to my baby.
- D. This medication will increase my prostaglandin production.
Correct answer: A
Rationale: The correct answer is A. Terbutaline works by blocking beta2-adrenergic receptors, leading to uterine smooth muscle relaxation and stopping contractions. It is commonly used to delay preterm labor. Choice B is incorrect because Terbutaline is not used to prevent vaginal bleeding. Choice C is incorrect because Terbutaline's primary action is not related to promoting blood flow to the baby. Choice D is incorrect because Terbutaline does not increase prostaglandin production; instead, it works by blocking beta2-adrenergic receptors.
2. When assessing a client with chronic Neutropenia receiving Filgrastim, what action should the nurse take to evaluate for an adverse effect of the medication?
- A. Assess for bone pain.
- B. Assess for right lower quadrant pain.
- C. Auscultate for crackles in the bases of the lungs.
- D. Auscultate the chest to listen for a heart murmur.
Correct answer: A
Rationale: The correct action when assessing a client receiving Filgrastim for chronic Neutropenia is to assess for bone pain. Bone pain is a known dose-related adverse effect of Filgrastim. Acetaminophen or opioid analgesics can be used to manage bone pain if necessary. Assessing for other types of pain, lung crackles, or heart murmurs would not be specific to the adverse effects of Filgrastim.
3. A healthcare professional is caring for an older adult client who has a new prescription for Digoxin and takes multiple other medications. Which of the following medications, when used concurrently with Digoxin, places the client at risk for Digoxin toxicity?
- A. Phenytoin
- B. Verapamil
- C. Warfarin
- D. Aluminum hydroxide
Correct answer: B
Rationale: Verapamil, a calcium-channel blocker, can increase digoxin levels, leading to Digoxin toxicity. When these medications are used together, the client is at an increased risk. Phenytoin (Choice A) does not significantly impact digoxin levels. Warfarin (Choice C) and aluminum hydroxide (Choice D) do not directly increase the risk of Digoxin toxicity. Therefore, the correct choice is Verapamil (Choice B) due to its potential to raise digoxin levels and cause toxicity.
4. A client is receiving heparin therapy. Which of the following laboratory values should the nurse monitor to evaluate the effectiveness of the therapy?
- A. PT
- B. aPTT
- C. INR
- D. Platelet count
Correct answer: B
Rationale: The corrected answer is B: aPTT. The activated partial thromboplastin time (aPTT) is the laboratory value used to monitor the effectiveness of heparin therapy. The aPTT should be maintained at 1.5 to 2 times the normal level to ensure therapeutic anticoagulation. Monitoring aPTT helps healthcare providers adjust heparin doses to achieve the desired anticoagulant effects and prevent complications such as bleeding or clotting. Choice A, PT (prothrombin time), is used to monitor warfarin therapy, not heparin. Choice C, INR (international normalized ratio), is also used to monitor warfarin therapy. Choice D, platelet count, is important for assessing the risk of bleeding, but it does not directly monitor the effectiveness of heparin therapy.
5. A client with breast cancer is receiving cyclophosphamide. What finding should the nurse monitor for?
- A. Hypertension
- B. Hyperglycemia
- C. Ototoxicity
- D. Hemorrhagic cystitis
Correct answer: D
Rationale: When a client is receiving cyclophosphamide, the nurse should monitor for hemorrhagic cystitis, a severe adverse effect caused by bladder irritation. It is essential to watch for signs such as hematuria, dysuria, and urinary frequency, and promptly intervene to prevent further complications. Hypertension (Choice A) is not typically associated with cyclophosphamide use. Hyperglycemia (Choice B) is not a common side effect of cyclophosphamide. Ototoxicity (Choice C) is more commonly associated with medications like aminoglycoside antibiotics or high-dose aspirin.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access